Short interest in Protalix BioTherapeutics Inc (AMEX:PLX) increased during the last reporting period, rising from 650.64K to 979.39K. This put 1.31% of the company's publicly available shares short.

In a report released on April 17, Julien Richer from Kepler Capital maintained a Buy rating on PLUXEE N.V. (PLX – Research Report), with a price target of €30.00. The company’s shares closed ...

San Jose, Calif., December 13, 2011—Altera Corporation (Nasdaq: ALTR) today announced it has successfully interoperated its 28-nm Stratix® V GX FPGA with PLX® Technology's (Nasdaq: PLXT) ExpressLane™ ...